Cadila Healthcare (India)

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

Samer Gawrieh, Mazen Noureddin, Nicole Loo et al. · Hepatology · 2021 · 335 citations · Full text

Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double‐blind, placebo‐controlled trial

John O’Brien, C. D. Adair, David F. Lewis et al. · Ultrasound in Obstetrics and Gynecology · 2007 · 293 citations · Full text

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Akash Khobragade, Suresh Bhate, Vijendra Ramaiah et al. · The Lancet · 2022 · 242 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system

Sandip B. Tiwari, T.K.S. Murthy, Mrsm Pai et al. · AAPS PharmSciTech · 2003 · 199 citations · Full text

Release Formulation, Hydrophobic Matrix System, Pharmaceutical Technology +4

Dual <scp>PPAR</scp>α/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental <scp>NASH</scp> models

Mukul R. Jain, Suresh Giri, Bibhuti Bhoi et al. · Liver International · 2017 · 197 citations · Full text